Veracyte (VCYT) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1,100%. A quarter ago, it was expected that this molecular diagnostic company would post a loss of $0.19 per share when it actually produced a loss of $0.02, delivering a surprise of 89.47%.Over the last four quarte ...

Q2 2024 Business and Financial Presentation August 6, 2024 © Veracyte, Inc. All rights reserved. © Veracyte, Inc. All rights reserved. Forward-looking statements and non-GAAP information This presentation contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with respect to 2024 financial and operating results; and our intentions with respect to our tests and products, for use in diagnosing an ...

财务业绩 - 总收入增长27%至1.144亿美元[2] - 总收入为200,281,000美元，同比增长28.5%[29] - 毛利为140,381,000美元，毛利率为66%[36] - 调整后EBITDA增长118%至2400万美元，占收入21%[14] - 公司2024年第二季度调整后EBITDA为2404万美元，同比增长118.1%[42] - 公司2024年第二季度非GAAP净利润为2340万美元，同比增长174.1%[43] - 公司2024年第二季度非GAAP每股收益为0.30美元，同比增长150%[44] - 公司2024年第二季度GAAP每股收益为0.07美元，同比增长158.3%[44] 业务发展 - 检测收入增长31%[9,10] - Decipher Prostate检测量创新高接近19,900例[6] - Afirma检测量创新高约15,700例，并获得Medicare报销覆盖[6] - 发布3项Decipher Prostate检测的临床研究论文[6] 现金流与资产 - 净利润增长168%至570万美元[13] - 现金流量改善，第二季度经营活动产生的净现金流为2060万美元[13] - 现金及现金等价物为235,915,000美元，较上年末增加19,461,000美元[32,35] - 应收账款为50,304,000美元，较上年末增加9,926,000美元[32] - 存货为19,258,000美元，较上年末增加3,130,000美元[32] - 经营活动产生的现金流入为20,609,000美元[34] - 投资活动产生的现金流入为108,000美元[34] 费用情况 - 研发费用为32,430,000美元，同比增长57.5%[37] - 销售及营销费用为47,998,000美元，同比增长8.4%[37] - 管理费用为57,955,000美元，同比增长25.7%[37] - 公司2024年第二季度GAAP总营业费用为1.404亿美元，同比增长10.4%[40] - 公司2024年第二季度非GAAP总营业费用为1.12亿美元，同比增长8.8%[40] - 公司2024年第二季度GAAP销售和营销费用为4800万美元，同比增长8.1%[38] - 公司2024年第二季度非GAAP销售和营销费用为4355万美元，同比增长9.1%[38] - 公司2024年第二季度GAAP一般及行政费用为5800万美元，同比增长13.1%[39] - 公司2024年第二季度非GAAP一般及行政费用为4036万美元，同比增长12.5%[39] 业绩指引 - 全年收入指引上调至4.32亿美元至4.38亿美元，同比增长20%至21%[16] - 年末现金及现金等价物预计将达到2.6亿美元至2.7亿美元[16]

Veracyte (VCYT) shares ended the last trading session 13.2% higher at $25.56. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.7% gain over the past four weeks.Last month, Veracyte presented new data suggesting the potential of novel molecular signatures to identify patients with thyroid nodules or cancer who have aggressive disease. The results, derived using its Afirma GRID (Genomic Resource for Intelligent Disc ...

It doesn't matter if you're a growth, value, income, or momentum-focused investor -- building a successful investment portfolio takes skill, research, and a little bit of luck.But what's the best way to find the right combination of stocks? Because funding things like your retirement, your kids' college tuition, or your short- and long-term savings goals will definitely require significant returns.Enter the Zacks Rank.What is the Zacks Rank?A unique, proprietary stock-rating model, the Zacks Rank uses earni ...

文章核心观点 - 公司的效率水平与其价格表现呈正相关,是衡量其盈利潜力的重要参数 [1] - 但衡量公司效率水平并非易事,需要考虑常用的效率比率 [2] 效率比率总结 应收账款周转率 - 反映公司信用管理和应收账款回收能力,值越高表示公司收款效率越高 [3] 资产利用率 - 反映公司将资产转化为产出的能力,值越高表示公司效率越高 [4] 存货周转率 - 反映公司存货管理水平,值越高表示存货水平较低,销售较好 [5] 营业利润率 - 反映公司控制营业费用的能力,值越高表示公司效率越高 [6] 筛选标准 - 上述4项效率比率均高于行业平均水平,表示公司效率优于同行 [8] - 同时具有较高的Zacks排名,表示公司具有较强的投资价值 [7] 优质公司案例 - Veracyte (VCYT): 一家全球诊断公司,平均4季度盈利惊喜达59.7% [9] - Steelcase (SCS): 一家办公环境设计制造商,平均4季度盈利惊喜达57.1% [10] - Applied Industrial Technologies (AIT): 一家工业产品分销商,平均4季度盈利惊喜达8.2% [11]

Veracyte (VCYT) closed the last trading session at $21.45, gaining 9.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $29.83 indicates a 39.1% upside potential. The mean estimate comprises six short-term price targets with a standard deviation of $5.71. While the lowest estimate of $21 indicates a 2.1% decline from the current price level, the most optimistic analyst expects the ...

After reaching an important support level, Veracyte (VCYT) could be a good stock pick from a technical perspective. VCYT surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend. The 50-day simple moving average is one of three major moving averages used by traders and analysts to determine support or resistance levels for a wide range of securities. But the 50-day is considered to be more important because it's the first marker of an up or down trend. Over the past four week ...

Irrespective of market conditions, companies with favorable efficiency levels are more likely to be investors’ choices. The reason is that a company with a favorable efficiency level is expected to offer impressive returns as it is believed to be positively correlated to its price performance. Efficiency ratio is an indication of a company’s financial health. It analyzes how efficiently a company uses its assets and liabilities internally. However, at times it becomes difficult to measure the efficiency lev ...

Veracyte, Inc. (VCYT) , a leading name in cancer diagnostics, is set to showcase compelling data from three studies demonstrating the capabilities of its Afirma GRID (Genomic Resource for Intelligent Discovery) tool at ENDO 2024 from Jun 1-4. These findings promise to enhance the personalization of thyroid cancer treatment, marking a significant step forward in the molecular testing landscape. By enhancing the depth and accuracy of molecular testing, Veracyte's Afirma GRID tool is poised to play a crucial r ...